Resultater fra diabetessårstudien i Russland (klinisk fase II) viser meget god sårtilheling hos de pasientene som har blitt behandlet med SBG. Både tilhelingstiden og andelen av p...
Resultater fra oral mukosittstudien viser at pasientene som har blitt behandlet med SBG har utviklet signifikant lavere grad av oral mukositt, sammenlignet med pasienter som har bl...
Biotec Pharmacon completes patient enrollment in phase II clinical trial for treatment of diabetic ulcers
Published 16.05.2006
Biotec Pharmacon has completed patient enrollment in a double-blinded, therapeutic exploratory clinical phase II trial to evaluate the efficacy of its soluble beta-1,3/1,6-glucan (...
Biotec Pharmacon (OSE: BIOTEC) has had good progress in the clinical trials with it’s pharmaceutical compound SBG. New clinical trial results are expected during the second quarter...
New clinical study for treatment of diabetic foot ulcers
Published 24.02.2006
Biotec Pharmacon enters into agreement with leading hospital in the UK to perform clinical trial (phase II) with SBG for treatment of chronic foot ulcers in diabetes patients....
Biotec Pharmacon to trial SBG/Rituxan combination therapy at the Radium Hospital
Published 02.12.2005
Biotec Pharmacon and the Radium Hospital/Norwegian National Hospital (Department of Clinical Cancer Research) have signed a Letter of Intent to perform clinical studies to evaluate...
Biotec Pharmacon to start SBG trials with Herceptin
Published 28.11.2005
Biotec Pharmacon and the Department of Oncology at Ullevål University Hospital in Oslo have announced that they are to commence clinical studies to evaluate the efficacy and safety...
